MedTrace Logo

Inducing Immune Quiescence to Prevent HIV Infection in Women

NCT02079077 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2019-10-10

Study results available
· View outcomes & findings →

Summary

In this project, the investigators want to analyse the capacity of Acetylsalicylic acid and hydoxychlroquin (HCQ) to induce an Immune Quiescence (IQ) phenotype, which has been previously associated with natural protection to HIV infection. This phenotype is characterized by lower expression of genes involved in cellular activation, lower resting levels of inflammatory cytokine production, lower level of systemic activated T cells, increased levels of systemic T regulatory, increased production of anti-viral anti-protease serpins at the female genital tract and reduced numbers of HIV target cells (mainly CD4+ CCR5+ T cells) in the FGT ( female genital tract).

The objective of this study is to determine if daily oral administration of Acetylsalicylic acid or hydroxychlroroquin can reduce systemic and mucosal immune activation in HIV negative women.

Conditions

Interventions

DRUG

Acetylsalicylic Acid (ASA)

Acetylsalicylic Acid (ASA) 81 mg. oral daily for two months

DRUG

Hydroxychloroquine (HCQ)

Hydroxychloroquine (HCQ) 200 mg. oral, daily for two months.

Sponsors & Collaborators

  • University of Nairobi

    collaborator OTHER

  • University of Manitoba

    lead OTHER

Principal Investigators

  • Keith R. Fowke, PhD · University of Manitoba

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2015-12-31
Completion
2018-01-01

Countries

  • Kenya

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02079077 on ClinicalTrials.gov